Nicholas J Vogelzang

Summary

Affiliation: Nevada Cancer Institute
Country: USA

Publications

  1. doi request reprint Chemotherapy for malignant pleural mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, Nevada 89135, USA
    Lancet 371:1640-2. 2008
  2. ncbi request reprint Standard therapy for the treatment of malignant pleural mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Lung Cancer 50:S23-4. 2005
  3. doi request reprint Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer
    Joseph D Khoury
    Dept of Pathology, Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA
    Am J Clin Pathol 134:964-9. 2010
  4. doi request reprint Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer
    Oscar B Goodman
    Department of Clinical Oncology, Nevada Cancer Institute, Las Vegas, 89135, USA
    Clin Genitourin Cancer 9:31-8. 2011
  5. doi request reprint Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer
    Jason C Gonzales
    Department of Laboratory Medicine, Nevada Cancer Institute, Las Vegas, 89135, USA
    Clin Genitourin Cancer 9:39-45. 2011
  6. doi request reprint Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma
    Nicholas J Vogelzang
    University of Nevada School of Medicine and US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA
    J Clin Oncol 31:670-5. 2013
  7. doi request reprint Conclusion and future directions
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Cancer J 14:330-2. 2008
  8. ncbi request reprint New agents in the management of advanced mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Semin Oncol 32:336-50. 2005
  9. ncbi request reprint Outcomes and prognosis in advanced renal cell carcinoma
    Matthew D Galsky
    Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA
    Expert Rev Anticancer Ther 7:839-45. 2007
  10. ncbi request reprint Emerging drugs for the treatment of metastatic renal cancer
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA
    Expert Opin Emerg Drugs 12:605-18. 2007

Collaborators

Detail Information

Publications69

  1. doi request reprint Chemotherapy for malignant pleural mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, Nevada 89135, USA
    Lancet 371:1640-2. 2008
  2. ncbi request reprint Standard therapy for the treatment of malignant pleural mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Lung Cancer 50:S23-4. 2005
    ..This doublet-based chemotherapy regimen is now the standard therapy for the first-line treatment of MPM...
  3. doi request reprint Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer
    Joseph D Khoury
    Dept of Pathology, Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA
    Am J Clin Pathol 134:964-9. 2010
    ..024). Increases in quantitative D-dimer levels correlate with progressive disease better than CTC counts in patients with refractory prostate cancer...
  4. doi request reprint Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer
    Oscar B Goodman
    Department of Clinical Oncology, Nevada Cancer Institute, Las Vegas, 89135, USA
    Clin Genitourin Cancer 9:31-8. 2011
    ..Multivariate analysis revealed baseline CTC as the only independent predictor of progression to CRPC. These data suggest that baseline CTC may identify those unlikely to benefit from ADT...
  5. doi request reprint Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer
    Jason C Gonzales
    Department of Laboratory Medicine, Nevada Cancer Institute, Las Vegas, 89135, USA
    Clin Genitourin Cancer 9:39-45. 2011
    ..Furthermore, miR-141 demonstrated high correlation with changes of the other biomarkers...
  6. doi request reprint Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma
    Nicholas J Vogelzang
    University of Nevada School of Medicine and US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA
    J Clin Oncol 31:670-5. 2013
    ..The 1.4-cm nodule has calcified and remains stable and metabolically inactive. He has no sequelae of chemotherapy or surgery, with a creatinine level of 1.35 mg/dL...
  7. doi request reprint Conclusion and future directions
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Cancer J 14:330-2. 2008
    ..This issue of The Cancer Journal has been devoted to reviewing clinical progress in the treatment of metastatic renal cancer, with an eye toward current needs and the likely future directions of the field...
  8. ncbi request reprint New agents in the management of advanced mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Semin Oncol 32:336-50. 2005
    ..Together with the newer drugs, rapidly emerging from the laboratory to be applied in the clinic, we have the hope of making further advances in the struggle against this disease...
  9. ncbi request reprint Outcomes and prognosis in advanced renal cell carcinoma
    Matthew D Galsky
    Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA
    Expert Rev Anticancer Ther 7:839-45. 2007
    ..This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma...
  10. ncbi request reprint Emerging drugs for the treatment of metastatic renal cancer
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA
    Expert Opin Emerg Drugs 12:605-18. 2007
    ..These agents are rapidly progressing through clinical testing in renal cancer and in other malignancies. This paper overviews the status of these investigational agents and anticipates areas of future research and development...
  11. doi request reprint Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate
    Fanny Chan
    Department of Medical Oncology, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Arch Pathol Lab Med 134:120-3. 2010
    ....
  12. ncbi request reprint Signal-transduction inhibitors in renal cell carcinoma
    Nicholas J Vogelzang
    Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV, USA
    BJU Int 99:1289-95. 2007
  13. doi request reprint Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy, The Nevada Cancer Institute, Las Vegas, NV 89135, USA
    BJU Int 102:162-5. 2008
    ..This brief review is intended to overview recent developments, and to identify advances that are likely to influence treatment decisions...
  14. ncbi request reprint Multimodality therapy in mesothelioma: role of chemotherapy
    Nicholas J Vogelzang
    Nevada Cancer Institute, 10, 000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135, USA
    Thorac Surg Clin 14:531-42. 2004
    ....
  15. ncbi request reprint Promising systemic therapy for renal cell carcinoma
    Matthew M Cooney
    Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV 89135, USA
    Curr Treat Options Oncol 6:357-65. 2005
    ..A review of the preclinical and early clinical development of some of these novel compounds will be discussed...
  16. doi request reprint Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors
    Oscar B Goodman
    Department of Clinical Oncology, Nevada Cancer Institute, One Breakthrough Way, Las Vegas, Nevada 89135, USA
    Cancer Epidemiol Biomarkers Prev 18:1904-13. 2009
    ..Patients received ongoing medical oncologic follow-up for up to 26 months, and overall survival status was documented...
  17. ncbi request reprint Treatment options in metastatic renal carcinoma: an embarrassment of riches
    Nicholas J Vogelzang
    J Clin Oncol 24:1-3. 2006
  18. ncbi request reprint Novel agents for the treatment of advanced kidney cancer
    Matthew M Cooney
    Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Clin Adv Hematol Oncol 2:664-70. 2004
    ..These compounds include antiangiogenic agents, raf kinase pathway inhibitors, and novel antimicrotubule agents. This review discusses some of the agents currently being explored for the treatment of advanced kidney cancer...
  19. ncbi request reprint A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer
    Andrew Artz
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Am J Clin Oncol 28:109-13. 2005
    ....
  20. ncbi request reprint A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
    Amy C Peterson
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, USA
    Invest New Drugs 24:141-9. 2006
    ..We combined different doses of Bryostatin-1 with IL-2 to determine effects on clinical response rate and T cell phenotype in patients with advanced kidney cancer...
  21. ncbi request reprint Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma
    Nick Pavlakis
    Royal North Shore Hospital, Department of Medical Oncology, St Leonards, NSW 2065, Australia
    Expert Opin Biol Ther 6:391-9. 2006
    ..At present, a Phase III trial of doxorubicin with or without ranpirnase is nearing completion in MM patients without prior chemotherapy or one prior chemotherapy regimen...
  22. ncbi request reprint Activities and accomplishments of the cancer and leukemia group B genitourinary committee
    Eric J Small
    University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 12:3596s-600s. 2006
    ..In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients...
  23. ncbi request reprint Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer
    James O Jin
    Section of Hematology Oncology, University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 5:150-4. 2006
    ..Despite the general acceptance of gemcitabine/cisplatin in metastatic bladder cancer, its role and tolerability in the adjuvant setting, in which renal insufficiency is common, is unclear...
  24. ncbi request reprint Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Urol 177:84-9; discussion 89. 2007
    ..We tested the efficacy and toxicity of adding paclitaxel to that regimen...
  25. ncbi request reprint The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Urol 177:531-4. 2007
    ....
  26. ncbi request reprint Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:247-56. 2007
    ..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome...
  27. ncbi request reprint Systemic therapy for metastatic urothelial carcinoma
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    BJU Int 101:795-803. 2008
  28. ncbi request reprint Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer
    Walter M Stadler
    University of Chicago, Illinois 60637, USA
    J Urol 170:1141-5. 2003
    ..To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined...
  29. ncbi request reprint Impact of race on survival in men with metastatic hormone-refractory prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 64:212-7. 2004
    ..To determine whether blacks with hormone-refractory prostate cancer have shorter survival compared with whites with the same disease...
  30. ncbi request reprint Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma
    Stanislaw M Mikulski
    Alfacell Corp, 225 Belleville Ave, Bloomfield, NJ 07003, USA
    J Clin Oncol 20:274-81. 2002
    ..Patients with unresectable and histologically confirmed malignant mesothelioma (MM) were eligible...
  31. ncbi request reprint Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, 00152, Rome, Italy
    Crit Rev Oncol Hematol 46:S105-15. 2003
    ..The molecular biology of these diseases is being unravelled and as knowledge accumulates, our ability to target these cancers will continue to increase...
  32. ncbi request reprint Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma
    Nicholas J Vogelzang
    Clin Lung Cancer 5:63-4. 2003
  33. ncbi request reprint Emerging insights into the biology and therapy of malignant mesothelioma
    Nicholas J Vogelzang
    University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Semin Oncol 29:35-42. 2002
    ....
  34. ncbi request reprint Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study
    Nancy B Davis
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 22:115-9. 2004
    ..Determine response rate, time to disease progression, and toxicity of the proteasome inhibitor PS-341 in patients with stage IV renal cell cancer...
  35. ncbi request reprint Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    Kenneth A Foon
    Abgenix, Inc, Fremont, CA, USA
    Int J Radiat Oncol Biol Phys 58:984-90. 2004
    ..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy...
  36. ncbi request reprint A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma
    Christopher W Ryan
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
    Cancer 94:2602-9. 2002
    ....
  37. ncbi request reprint Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results
    Brian I Rini
    University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 20:2017-24. 2002
    ..To evaluate the feasibility and safety of nonmyeloablative allogeneic stem-cell transplantation in patients with metastatic renal cell cancer (RCC) and to evaluate efficacy with respect to engraftment and tumor regression...
  38. ncbi request reprint Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    Nicholas J Vogelzang
    University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA
    J Clin Oncol 21:2636-44. 2003
    ..We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone...
  39. ncbi request reprint Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Rd, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
    J Clin Oncol 22:3003-15. 2004
    ....
  40. ncbi request reprint The emerging role of antifolates in the treatment of malignant pleural mesothelioma
    Karim Fizazi
    Institut Gustave Roussy, Villejuif, France
    Semin Oncol 29:77-81. 2002
    ..In both trials, survival is the main endpoint. These trials will help to define the role of these new antifolates in malignant pleural mesothelioma...
  41. ncbi request reprint Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei 100, Taiwan
    Cancer 106:1269-75. 2006
    ..The authors developed a regimen that was designed to maintain efficacy, while reducing toxicities...
  42. ncbi request reprint A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
    Apurva A Desai
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Cancer 95:1629-36. 2002
    ....
  43. ncbi request reprint Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
    D Andrew Loblaw
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 25:1596-605. 2007
    ..To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa)...
  44. doi request reprint Pain predicts overall survival in men with metastatic castration-refractory prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University, and Cancer and Leukemia Group B Statistical Center, Durham, NC, USA
    J Clin Oncol 26:2544-9. 2008
    ..The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores...
  45. ncbi request reprint Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer
    Richard L Schilsky
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 20:582-7. 2002
    ..The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination...
  46. ncbi request reprint Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:1232-7. 2003
    ..To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC)...
  47. ncbi request reprint Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial
    Michael A Carducci
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    J Clin Oncol 21:679-89. 2003
    ..To evaluate the efficacy and safety of atrasentan (ABT-627), an endothelin-A receptor antagonist, in the treatment of asymptomatic, hormone-refractory prostatic adenocarcinoma...
  48. ncbi request reprint Future directions for gemcitabine in the treatment of genitourinary cancer
    Nicholas J Vogelzang
    Department of Medicine and Surgery Urology, University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
    Semin Oncol 29:40-5. 2002
    ..These data suggest the need for further trials of gemcitabine alone or in combinations in genitourinary cancer patients...
  49. ncbi request reprint Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study
    Ellis G Levine
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263 0001, USA
    Cancer 94:665-72. 2002
    ....
  50. doi request reprint Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904
    Robert A Kratzke
    Division of Hematology Oncology Transplant, The University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 3:417-21. 2008
    ..This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16INK4a via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC)...
  51. ncbi request reprint Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity
    Brian I Rini
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, U S A
    J Immunother 25:269-77. 2002
    ....
  52. ncbi request reprint Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
    H Barton Grossman
    M D Anderson Cancer Center, Houston, USA
    N Engl J Med 349:859-66. 2003
    ..We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy...
  53. ncbi request reprint Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480
    Eric J Small
    Comprehensive Cancer Center, University of California San Francisco, 1600 Devisadero Street, Third Floor, San Francisco, CA 94115, USA
    J Clin Oncol 20:3369-75. 2002
    ..To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent...
  54. ncbi request reprint Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implications
    Jun Sugimura
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Urology 64:362-8; discussion 368. 2004
    ..MN is the most common tumor of the neonatal kidney. It occurs in a younger age group than the Wilms tumor (WT). To date, very little is known about the etiology and pathogenesis of MN...
  55. ncbi request reprint Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
    Med Phys 31:1105-15. 2004
    ..93). We have developed computerized techniques for the measurement of mesothelioma tumor thickness in CT scans. These techniques achieved varying levels of agreement with measurements made by human observers...
  56. ncbi request reprint The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480
    Daniel J George
    Divisions of Urology and Medical Oncology, Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 2771, USA
    Clin Cancer Res 11:1815-20. 2005
    ..In order to evaluate its prognostic significance in metastatic HRCaP patients, we measured IL-6 in plasma collected at baseline from patients in a large cooperative group study [Cancer and Leukemia Group B 9480 (CALGB 9480)]...
  57. ncbi request reprint A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer
    Walter M Stadler
    University of Chicago Phase II Consortium, University of Chicago, Section of Hematology Oncology, Chicago, Illinois 60637, USA
    Clin Cancer Res 10:3365-70. 2004
    ..In vitro assessment of SU5416 on PSA secretion was assessed in the LNCaP cell line. Baseline serum basic fibroblast growth factor and plasma vascular endothelial growth factor (VEGF) were explored as prognostic factors...
  58. ncbi request reprint Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study
    Mary Ellen Taplin
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 66:386-91. 2005
    ..Plasma CgA levels in patients with prostate cancer may reflect the extent of the tumor neuroendocrine phenotype...
  59. ncbi request reprint Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004
    ..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...
  60. ncbi request reprint Gene expression profiling of renal medullary carcinoma: potential clinical relevance
    Ximing J Yang
    Department of Pathology, The University of Chicago, Chicago, Illinois, USA
    Cancer 100:976-85. 2004
    ..To the authors' knowledge, very little is known to date regarding the underlying molecular genetics of this tumor, and no effective therapy has been established...
  61. ncbi request reprint Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Acad Radiol 12:1301-9. 2005
    ..To evaluate the clinical acceptability of semiautomated methods for the measurement of mesothelioma tumor thickness in computed tomography (CT) scans...
  62. ncbi request reprint A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated?
    Matthew M Cooney
    Division of Hematology Oncology, University Hospitals of Cleveland, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Curr Urol Rep 5:19-24. 2004
    ..Even with this aggressive approach, most patients eventually will die from their kidney cancer; therefore, every patient with metastatic disease should be considered for enrollment into clinical trials...
  63. ncbi request reprint American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer
    D Andrew Loblaw
    Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 22:2927-41. 2004
    ..The focus of this document is on the use, combinations, and timing of various forms of androgen deprivation therapy (ADT) for the palliation of men with androgen-sensitive disease...
  64. ncbi request reprint A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813
    William K Oh
    Lank Center for Geritourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:2592-8. 2003
    ..The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma...
  65. ncbi request reprint Variability in mesothelioma tumor response classification
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
    AJR Am J Roentgenol 186:1000-6. 2006
    ..In addition, the performance of a semiautomated measurement method was evaluated...
  66. ncbi request reprint Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480
    Peter A Humphrey
    Washington University Medical Center, St Louis, MO 63110, USA
    Clin Genitourin Cancer 4:269-74. 2006
    ..Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma...
  67. ncbi request reprint Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA
    J Urol 176:81-6. 2006
    ..We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer...
  68. ncbi request reprint Molecular subclassification of kidney tumors and the discovery of new diagnostic markers
    Masayuki Takahashi
    Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA
    Oncogene 22:6810-8. 2003
    ..We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications...
  69. ncbi request reprint Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies
    Christopher W Ryan
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
    Clin Cancer Res 10:4406-11. 2004
    ..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies...